What are the possible unifying diagnoses for a patient presenting with uveitis, interstitial lung disease, and autoimmune pancreatitis?

IgG4-Related Disease is the Primary Unifying Diagnosis

The triad of uveitis, interstitial lung disease (ILD), and autoimmune pancreatitis most strongly suggests IgG4-related disease (IgG4-RD), which is a systemic immune-mediated condition that can simultaneously affect multiple organs including the pancreas, lungs, and eyes. This diagnosis should be your leading consideration when encountering this specific constellation of findings.

Diagnostic Approach

Primary Consideration: IgG4-Related Disease

IgG4-RD characteristically presents with:

• Type 1 autoimmune pancreatitis (lymphoplasmacytic sclerosing pancreatitis) as the pancreatic manifestation
• ILD with nodular lesions, ground-glass opacities, pleural thickening, or effusions as documented in 11-15% of AIP patients 1
• Ocular involvement including orbital disease and, less commonly, uveitis

The diagnosis requires:

• Elevated serum IgG4 levels (>135 mg/dL, though levels >417 mg/dL are highly suggestive) 2
• Characteristic imaging findings: diffuse pancreatic enlargement with peripheral capsule-like rim, main pancreatic duct narrowing, and potential bile duct involvement 3
• Histopathology showing IgG4-positive plasma cell infiltration (>10 IgG4+ cells per high-power field) when tissue is available 4

Secondary Consideration: Sjögren's Syndrome with Overlap Features

Sjögren's syndrome represents the second most likely unifying diagnosis, particularly given:

• High prevalence of pulmonary involvement in Sjögren's patients, with ILD being a recognized complication 5
• Association with autoimmune pancreatitis through overlap syndromes 2
• Uveitis as a recognized extra-glandular manifestation 6

For Sjögren's evaluation, obtain:

• Anti-SS-A (Ro) and anti-SS-B (La) antibodies
• Minor salivary gland biopsy showing focal lymphocytic sialadenitis
• Detailed history of sicca symptoms (dry eyes, dry mouth) 5

Tertiary Consideration: Anti-Synthetase Syndrome

This diagnosis should be considered when:

• ILD is the dominant feature with inflammatory myopathy
• Mechanic's hands, myalgia, and elevated creatine kinase are present
• Anti-aminoacyl-tRNA synthetase antibodies (particularly anti-Jo-1, anti-PL-7, anti-PL-12) are positive 2

However, anti-synthetase syndrome less commonly explains the autoimmune pancreatitis component unless there is overlap with IgG4-RD or Sjögren's 2.

Critical Diagnostic Workup

Immediate Laboratory Testing

1. Serum IgG4 level - single most important initial test
2. Complete autoimmune panel: ANA, RF, anti-SS-A/Ro, anti-SS-B/La, anti-CCP
3. Myositis panel: anti-synthetase antibodies (Jo-1, PL-7, PL-12, EJ, OJ), creatine kinase
4. Inflammatory markers: ESR, CRP
5. Pancreatic enzymes: lipase, amylase

Essential Imaging

1. High-resolution CT chest - evaluate ILD pattern, nodules, ground-glass opacities, pleural involvement 5, 1
2. MRI pancreas with MRCP - assess for diffuse enlargement, capsule-like rim, duct narrowing 3
3. Complete pulmonary function tests including spirometry, DLCO, and lung volumes 5

Tissue Confirmation

• Pancreatic biopsy (EUS-guided FNA) or thoracoscopic lung biopsy for IgG4+ plasma cell quantification when diagnosis remains uncertain 4
• Minor salivary gland biopsy if Sjögren's is strongly suspected 2

Important Clinical Pitfalls

Do not rely on serologic biomarkers alone - IgG4 levels can be normal in organ-limited disease, and elevated IgG4 is not specific 5. Tissue diagnosis remains the gold standard when feasible.

Recognize that these conditions frequently overlap - the case report literature documents patients with simultaneous IgG4-RD, Sjögren's syndrome, and anti-synthetase syndrome 2, suggesting shared immunopathogenic mechanisms.

Screen for additional organ involvement - IgG4-RD commonly affects kidneys (tubulointerstitial nephritis), retroperitoneum (retroperitoneal fibrosis), salivary glands, and lymph nodes. Comprehensive evaluation prevents missed diagnoses 1.

Monitor for malignancy risk - particularly lymphoproliferative disorders (MALT lymphoma) in Sjögren's patients with pulmonary involvement 5.

Risk Stratification for ILD Progression

Given the presence of ILD, assess progression risk using 7, 8:

• Baseline extent of fibrosis on HRCT - extent >20% predicts worse outcomes
• Baseline FVC and DLCO - lower values indicate higher risk
• Serial PFT decline - FVC decline >10% or DLCO decline >15% over 6-12 months defines progression
• Radiologic progression - increasing fibrosis on serial HRCT

Patients with progressive fibrosing ILD phenotype require urgent immunosuppression and consideration of antifibrotic therapy (nintedanib or pirfenidone) regardless of underlying diagnosis 8.